Abstract
Since the onset of the COVID-19 pandemic, researchers mainly examined how socio-economic, demographic, and environmental factors are related to disparities in SARS-CoV-2 infection rates. However, we don’t know the extent to which racial disparities in environmental exposure are related to racial disparities in SARS-CoV-2 infection rates. To address this critical issue, we gathered black vs. white infection records from 1416 counties in the contiguous United States. For these counties, we used 30m-spatial resolution land cover data and racial mappings to quantify the racial disparity between black and white people’s two types of environmental exposure, including exposures to various types of landscape settings and urban development intensities. We found that racial disparities in SARS-CoV-2 infection rates and racial disparities in exposure to various types of landscapes and urban development intensities were significant and showed similar patterns. Specifically, less racial disparity in exposure to forests outside park, pasture/hay, and urban areas with low and medium development intensities were significantly associated with lower racial disparities in SARS-CoV-2 infection rates. Distance was also critical. The positive association between racial disparities in environmental exposures and racial disparity in SARS-CoV-2 infection rates was strongest within a comfortable walking distance (approximately 400m).
Highlights
Racial dot map and landcover map were used for population-weighted analysis.
Racial disparity in environmental exposures and SARS-CoV-2 infection were linked.
Forests outside park are the most beneficial landscape settings.
Urban areas with low development intensity are the most beneficial urban areas.
Landscape and urban exposures within the 400m buffer distances are most beneficial.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by University Research Committee of The University of Hong Kong (grant: 102010054.088616. 01100.302.01), The University of Hong Kong HKU-100 Scholars Fund, and National Natural Science Foundation of China (No. 51908202).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Centers for Disease Control and Prevention (CDC, https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Restricted-Access-Detai/mbd7-r32t)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
